Apimeds Pharmaceuticals US, Inc.
No SEC Form 4 filings for $APUS in the last 30 days.
See all $APUS insider activity →MindWave Innovations (APUS) signed a 2-year agreement with BlockAssure to build and operate AssureChain, an insurance and reinsurance network on MindChain. MindWave will earn development fees and receive 20% of AssureCoin's total supply. The agreement took effect on Oct. 4, 2026, and includes automatic renewal clauses.
Apimeds Pharmaceuticals US (APUS) appointed Eric Sherb as CFO on October 1, 2026, following Erick Frim's resignation as Interim CFO on September 29, 2026. Sherb has 18+ years of capital markets experience and is a Certified Public Accountant. Frim's departure was not due to any disagreement with the company.
Apimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Interim Chief Financial Officer On September 29, 2026, Erick Frim notified Apimeds Pharmaceuticals US, Inc.,
Over the past 7 days, AlphAI's AI scored 1 news story mentioning APUS (Apimeds Pharmaceuticals US, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent APUS coverage spans corporate actions, financial news and technology.
The contract adds a recurring services revenue source for the subsidiary, potentially boosting APUS's top line over the next two years.
The CFO transition may cause modest short‑term price pressure as investors evaluate the new leadership.
Officer change with modest compensation; no immediate operational impact.
The contract adds a new revenue stream and positions APUS in the emerging ecosystem‑finance market.
Blockchain partnership opens new revenue stream in conservation‑credit trading.
AlphAI scores every news story that mentions APUS with an AI model for sentiment and relevance, and aggregates insider trades from Apimeds Pharmaceuticals US, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MindWave Innovations (APUS) signed a 2-year agreement with BlockAssure to build and operate AssureChain, an insurance and reinsurance network on MindChain. MindWave will earn development fees and receive 20% of AssureCoin's total supply. The agreement took effect on Oct. 4, 2026, and includes automatic renewal clauses.
2 min readApimeds Pharmaceuticals US (APUS) appointed Eric Sherb as CFO on October 1, 2026, following Erick Frim's resignation as Interim CFO on September 29, 2026. Sherb has 18+ years of capital markets experience and is a Certified Public Accountant. Frim's departure was not due to any disagreement with the company.
1 min readApimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Interim Chief Financial Officer On September 29, 2026, Erick Frim notified Apimeds Pharmaceuticals US, Inc.,
1 min readApimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 MindWave Innovations Inc to Power AQUAEChain with Its MindChain Blockchain Infrastructure Agreement strengthens MindWave’s position as a technology provider for ecosystem finance and environmental markets MATAWAN, New Jersey — September 24, 2026 — MindWave Innovation
1 min readMeta (META) rose 4.5% to $777.59, driven by AI strategy. Everpure (P) surged 11.15% to $121.88, reaffirming fiscal 2027 guidance. Akamai (AKAM) fell 6.78% to $110.41, then jumped 20.65% after-hours on a $11.6B AI deal. Apimeds (APUS) soared 114.85% to $4.92 on a blockchain agreement. Costco (COST) dipped 0.91% to $896.48 despite beating Q4 estimates.
3 min readBiotech stocks APUS, PFSA, GCTK, and ARCT saw notable moves. APUS surged 130% without specific news, plans Phase 3 trial for Apitox. PFSA up 49.14% after ISO 13485 certification progress. GCTK raised $3.1M via stock offering, up 25.62%. ARCT rose 6.77% on Phase 2 results and LUNAR 2.0 platform news. Q2 losses reported for APUS.
3 min readApimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 10, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”), MindWave Innovations Inc, a Delaware corporation and a wholly owned subsidiary of the Company, Erik Emerson, Lokahi Therapeutic
1 min readApimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 19, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”), entered into an Assignment and Transfer Agreement of Certain Apitox Rights (the “ Assignment Agreement ”) with FreeT Inc., a comp
2 min readPremarket trading on Friday shows significant moves in several stocks. RFAI surged 489% to $75.00, SUGP rose 46% to $4.04, and USDE climbed 18% to $4.72. Conversely, DFNS dropped 18% to $20.05, OSIS fell 15% to $186.47, and OPHC declined 11% to $8.21. These early swings may indicate momentum for the regular trading session.
1 min readApimeds Pharmaceuticals US, Inc. (APUS) has filed a Form NT 10-Q with the SEC, indicating that it will be submitting its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, late. The company stated it requires additional time to finalize its financial statements and expects to file the report within the five-calendar-day extension period permitted under Rule 12b-25. No significant change in the results of operations from the corresponding period for the last fiscal year is anticipated.
2 min read
